Testing every kilogram of every incoming container is practically impossible for facilities handling hundreds of drums, bags, or containers daily. Instead, pharmaceutical companies rely on scientifically designed statistical sampling plans, robust Good Manufacturing Practices (GMP), and comprehensive risk assessment methodologies to obtain representative samples that accurately reflect the quality of the entire lot.

GLP-1 drugs like semaglutide and liraglutide are revolutionizing diabetes and obesity care by enhancing glucose control and driving weight loss. Their complex manufacturing spanning peptide synthesis, formulation, sterile injectables, and cold-chain logistics poses challenges but also opportunities. With global demand soaring and annual sales projected to exceed $100 billion by 2030, supply chain bottlenecks and device shortages remain critical barriers. As patents for blockb